EGFR and hepatocellular carcinoma: HMOX1 altered the resistance of HCC to sorafenib by modulating the expression of ABC transporters (Zhu et al., 2022), The activation of the EGFR-STAT3-ABCB1 pathway was closely associated with chemotherapy drug resistance (Hu et al., 2022).